Biomarkers.

Background: MRI offers potential noninvasive detection of Alzheimer's micropathology. The AD hippocampus exhibits microscopic pathological changes such as tau tangles, iron accumulation and late-stage amyloid. Validating these changes from ultra-high-resolution ex-vivo MRI through histology is challenging due to nonlinear 3D deformations between MRI and histological samples.

Biomarkers.

Background: Specimen analysis is crucial for identifying imaging and neuropathological signatures. Histology is the gold-standard, but sample preparation and sectioning induce tissue deformations which hinder quantitative analysis or registration of histology to 3D MRI providing a challenge to the development of MRI biomarkers. Overall, we aim to develop a workflow to correlate histology with high-resolution MRI at a microscopic level (Figure 1), Here, we evaluate a critical step in this process - the section quality from tissue mounting techniques, comparing: A) traditional water bath (Figure 1F), and B) tape transfer (Figure 1G), for the purpose of image segmentation and correlation with high-resolution MRI.

Alzheimer's Imaging Consortium.

Background: Specimen analysis is crucial for identifying imaging and neuropathological signatures. Histology is the gold-standard, but sample preparation and sectioning induce tissue deformations which hinder quantitative analysis or registration of histology to 3D MRI providing a challenge to the development of MRI biomarkers. Overall, we aim to develop a workflow to correlate histology with high-resolution MRI at a microscopic level (Fig.

Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.

Background: -related schwannomatosis ( -SWN) is a debilitating condition that calls for robust treatment options. The defining feature of -SWN is the presence of bilateral vestibular schwannomas (VSs), which grow over time and can result in irreversible sensorineural hearing loss, significantly affecting the quality of life for those affected. At present, there are no FDA-approved medications specifically for treating VS or related hearing loss.